Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation

We report on a case of metastatic urothelial bladder carcinoma (mUBC) treated with anlotinib combined with sintilimab. A 69-year-old male was diagnosed with non-muscle invasive bladder cancer (NMIBC). He received transurethral resection of bladder tumor (TURBT) and intravesical gemcitabine chemother...

Full description

Bibliographic Details
Main Authors: Jian-zhou Cao, Wei Wu, Jin-feng Pan, Hong-wei Wang, Jun-hui Jiang, Qi Ma
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Oncology
Subjects:
anlotinib
sintilimab
immunotherapy
targeted therapy
metastatic urothelial bladder carcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.643413/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.643413/full

Similar Items